[EN] HETEROCYCLIC COMPOUNDS USEFUL AS HPK1 INHIBITORS [FR] COMPOSÉS HÉTÉROCYCLIQUES UTILES EN TANT QU'INHIBITEURS DE HPK1
摘要:
Disclosed herein are compounds of Formula (I) : or pharmaceutically acceptable salts thereof. Also disclosed are methods of using such compounds to modulate or inhibit the enzymatic activity of hematopoietic progenitor kinase (HPK1), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of ΗΡK1-associated diseases or disorders, e.g. viral infections and cancers.
[EN] HETEROCYCLIC COMPOUNDS USEFUL AS HPK1 INHIBITORS [FR] COMPOSÉS HÉTÉROCYCLIQUES UTILES EN TANT QU'INHIBITEURS DE HPK1
摘要:
Disclosed herein are compounds of Formula (I) : or pharmaceutically acceptable salts thereof. Also disclosed are methods of using such compounds to modulate or inhibit the enzymatic activity of hematopoietic progenitor kinase (HPK1), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of ΗΡK1-associated diseases or disorders, e.g. viral infections and cancers.
[EN] HETEROCYCLIC COMPOUNDS USEFUL AS HPK1 INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILES EN TANT QU'INHIBITEURS DE HPK1
申请人:[en]SILEXON AI TECHNOLOGY CO., LTD.
公开号:WO2023138612A1
公开(公告)日:2023-07-27
Disclosed herein are compounds of Formula (I) : or pharmaceutically acceptable salts thereof. Also disclosed are methods of using such compounds to modulate or inhibit the enzymatic activity of hematopoietic progenitor kinase (HPK1), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of ΗΡK1-associated diseases or disorders, e.g. viral infections and cancers.